Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin detemir versus insulin glargine in basal-bolus therapy for type 2 diabetes
2004-000087-27Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Insulin detemir + insulin aspart with Insulin glargine + insulin aspart (2 arms). Primary endpoint: HbA1c after 52 weeks of treatment. Started Jun 2004; status: completed.
02
Drugs
insulin detemirinsulin glargineinsulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-000087-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000087-27.